Biomark Diagnostics Inc. (CSE:BUX)

Ligand Pharmaceuticals Revenue

In the fiscal year ending March 31, 2025, Biomark Diagnostics had annual revenue of 154.22K CAD, down -5.52%. Biomark Diagnostics had revenue of 38.99K in the quarter ending March 31, 2025, a decrease of -2.04%.

• Revenue: 154.22K
• Revenue Growth: -5.52%
• P/S Ratio: 227.63
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 35.10M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	154.22K	-9.00K	-5.52%
Mar 31, 2024	163.22K	9.73K	6.34%
Mar 31, 2023	153.49K	109.56K	249.38%
Mar 31, 2022	43.93K	-	-
Mar 31, 2021	-	-	-